Stock 4568 DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Delayed Japan Exchange
Other stock markets
 08:42:04 2024-04-29 pm EDT 		5-day change 1st Jan Change
5,298 JPY +5.75% Intraday chart for Daiichi Sankyo Co., Ltd. +13.02% +36.11%
Apr. 29 AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement MT
Apr. 29 AstraZeneca makes progress with Truqap and Enhertu cancer treatments AN

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
MT
AstraZeneca makes progress with Truqap and Enhertu cancer treatments
AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study
MT
Hipgnosis Songs Fund backs new Blackstone bid
AN
Scholz pledges further support for the pharmaceutical industry
DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024
MT
AstraZeneca upbeat as cancer drugs underpin sales growth
AN
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.
CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.
CI
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark
MT
AstraZeneca hails neurological data for Ultomiris, Soliris
AN
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
RE
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer
CI
AstraZeneca, Daiichi make US progress with licence approvals
AN
FTSE 100 Ends Lower; UK Manufacturing Sector Escapes Contraction
MT
AstraZeneca and Daiichi make US progress with latest licence approvals
AN
AstraZeneca, Daiichi Sankyo Seek US FDA Approval for Breast Cancer Drug
MT
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
CI
Final dividend
FA
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. News Daiichi Sankyo Co., Ltd.
  5. Highlights